We are live on
!
Find out more
TCM
Tamarack Capital Management Portfolio holdings
AUM
$840M
1-Year Est. Return
19.47%
This Fund
S&P 500
This Quarter
Est. Return
+1.77%
1 Year Est. Return
+19.47%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$870M
AUM Growth
+$111M
(+15%)
Cap. Flow
+$114M
Cap. Flow
% of AUM
13.05%
Top 10 Holdings %
Top 10 Hldgs %
66.83%
Holding
47
New
8
Increased
18
Reduced
6
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PDCO
Patterson Companies, Inc.
PDCO
|
+$25.6M |
| 2 |
Becton Dickinson
BDX
|
+$24.2M |
| 3 |
Quest Diagnostics
DGX
|
+$22.2M |
| 4 |
Lantheus
LNTH
|
+$11.3M |
| 5 |
Bruker
BRKR
|
+$10.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$24.9M |
| 2 |
Inogen
INGN
|
+$18.2M |
| 3 |
DexCom
DXCM
|
+$14M |
| 4 |
Pfizer
PFE
|
+$13.6M |
| 5 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$12.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 56.95% |
| 2 | Technology | 1.93% |
| 3 | Industrials | 0.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Perrigo
PRGO
$1.4B
| $9.24M | 1.06% |
50,000
-52,000
| -51% | -$9.91M |
|
27
Bio-Techne
TECH
$11.2B
| $7.95M | 0.91% |
323,116
-136,884
| -30% | -$3.42M |
|
|
AMRN
28
Amarin Corp
AMRN
$299M
| $7.93M | 0.91% |
+161,235
| New | +$7.26M |
|
|
OXFD
29
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $6.99M | 0.8% |
504,668
+52,535
| +12% | +$711K |
|
|
HMSY
30
DELISTED
HMS Holdings Corp.
HMSY
| $5.65M | 0.65% |
+329,246
| New | +$5.57M |
|
31
Cerus
CERS
$433M
| $4.49M | 0.52% |
+865,170
| New | +$4.1M |
|
|
32
Inogen
INGN
$175M
| $3.35M | 0.38% |
75,000
-475,000
| -86% | -$18.2M |
|
|
STRM
33
DELISTED
Streamline Health Solutions
STRM
| $3.19M | 0.37% |
75,867
| – | – |
|
34
Supernus Pharmaceuticals
SUPN
$2.59B
| $2.55M | 0.29% |
+150,000
| New | +$2.13M |
|
|
35
DexCom
DXCM
$31.5B
| – | – |
-900,000
| Closed | -$14M |
|
36
CALL
MiMedx Group
MDXG
$602M
| – | – |
-500,000
| Closed | -$5.2M |
|
|
37
Pfizer
PFE
$143B
| – | – |
-412,323
| Closed | -$13.6M |
|
38
PUT
ResMed
RMD
$30.6B
| – | – |
-60,000
| Closed | -$4.31M |
|
39
Steris
STE
$22.3B
| – | – |
-10,000
| Closed | -$703K |
|
|
40
Teva Pharmaceuticals
TEVA
$40.8B
| – | – |
-400,000
| Closed | -$24.9M |
|
41
Thermo Fisher Scientific
TMO
$213B
| – | – |
-50,000
| Closed | -$6.72M |
|
|
HNGR
42
DELISTED
Hanger Inc.
HNGR
| – | – |
-100,000
| Closed | -$2.27M |
|
|
KERX
43
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| – | – |
-950,000
| Closed | -$12.1M |
|
|
WINT
44
DELISTED
Windtree Therapeutics Inc
WINT
| – | – |
-16,824
| Closed | -$280K |
|
|
FEIC
45
DELISTED
FEI COMPANY
FEIC
| – | – |
-35,180
| Closed | -$2.69M |
|
|
OREX
46
DELISTED
Orexigen Therapeutics, Inc.
OREX
| – | – |
-100,000
| Closed | -$7.83M |
|
Similar funds
RI
CWA
GHF
F
TRV
BMCMI
GACM
AH
Tamarack Capital Management's Q2 2015 Portfolio in Review
As of Q2 2015, Tamarack Capital Management held 47 positions worth $870M, up 15% from $759M the previous quarter. Its ten largest holdings account for 67% of the portfolio.
Tamarack Capital Management deployed $114M of net new capital in Q2 2015, opening 8 new positions and adding to 18 existing holdings. Its largest new stake was Lantheus: 1,770,918 shares worth $11M.
By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 58% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Inogen, an estimated $18.2M trimmed.
- Tamarack Capital Management's largest Q2 2015 buy was Lantheus: 1,770,918 shares worth $11M.
- Tamarack Capital Management added most to Patterson Companies, Inc. in Q2 2015, an estimated $25.6M increase.
- Tamarack Capital Management's biggest Q2 2015 reduction was Inogen, cutting an estimated $18.2M.
- Tamarack Capital Management fully exited Teva Pharmaceuticals in Q2 2015, selling an estimated $24.9M.
- Tamarack Capital Management's ten largest holdings make up 67% of its $870M portfolio in Q2 2015.
- Tamarack Capital Management opened 8 new positions and closed 12 in Q2 2015.
- Tamarack Capital Management's portfolio value rose 15% quarter-over-quarter to $870M.
Based on Tamarack Capital Management's 13F filing for Q2 2015, filed 11 Aug 2015.